Article
KIT, PDGFRA, and BRAF mutational spectrum impacts on the natural history of imatinib-naive localized GIST: a population-based study.
The American journal of surgical pathology - 1 Jul 2015
Rossi Sabrina, Gasparotto Daniela, Miceli Rosalba, Toffolatti Luisa, Gallina Giovanna, Scaramel Enrico, Marzotto Alessandra, Boscato Elena, Messerini Luca, Bearzi Italo, Mazzoleni Guido, Capella Carlo, Arrigoni Gianluigi, Sonzogni Aurelio, Sidoni Angelo, Mariani Luigi, Amore Paola, Gronchi Alessandro, Casali Paolo G, Maestro Roberta, Dei Tos Angelo P
Abstract excerpt
The mutation status of KIT or PDGFRA notoriously affects the response of advanced gastrointestinal stromal tumors (GISTs) to tyrosine kinase inhibitors. Conversely, it is currently still unclear whether mutation status impinges on the prognosis of localized, untreated GISTs. Hence, at present, this variable is not included in decision making for adjuvant therapy. A series of 451 primary localized GISTs were...
Topics
Join the communities discussing this publication.